Drug Container Interactions: Why Packaging Must Be Treated as a Critical Quality Attribute Across the Product Lifecycle

 

Introduction

Pharmaceutical packaging has traditionally been viewed as a downstream activity selected after formulation and process development are finalized. However, increasing scientific evidence and regulatory expectations have demonstrated that packaging is not a passive component. Instead, it is an integral part of the drug product system that can significantly influence quality, safety, and efficacy.

Drug container interactions can lead to chemical, physical, or biological changes in the product, making packaging a Critical Quality Attribute (CQA) that must be addressed throughout the product lifecycle.

Key Drug–Container Interaction Mechanisms

1. Silicone Oil Interactions

Silicone oil is widely used as a lubricant in prefilled syringes and cartridges. Nonuniform silicone distribution and silicone droplet formation can contribute to protein aggregation, subvisible particles, and dose variability. Interaction between silicone and biologics is a growing concern for immunogenicity and product performance.

2. Extractables and Leachables (E&L)

Extractables and leachables are chemical compounds that can migrate from packaging materials into the drug product. These compounds may originate from plastics, elastomers, adhesives, inks, and coatings. Regulatory agencies expect comprehensive E&L assessments using risk based and lifecycle approaches to ensure patient safety.

3. Glass Delamination

Glass delamination is the separation of thin glass flakes from the inner surface of vials, often driven by chemical attack, thermal stress, and manufacturing conditions. Delamination can lead to visible and subvisible particles, triggering recalls and regulatory actions. Proper glass selection, surface treatments, and stability monitoring are essential risk mitigation strategies.

4. Material Incompatibilities and Degradation

Packaging materials can interact with drug formulations through adsorption, absorption, oxidation, hydrolysis, or photodegradation. Proteins may adsorb to container surfaces, while small molecules may degrade due to light transmission or oxygen permeation. Compatibility studies must be integrated into formulation and packaging selection decisions.

5. Fogging and Condensation

Fogging is commonly observed in plastic packaging systems and may result from migration of low molecular weight compounds or condensation phenomena. While often considered cosmetic, fogging can affect visual inspection and indicate underlying material migration issues.

6. Particles: Origins and Characterization

Particles can originate from packaging components such as glass, elastomers, silicone, plastics, or manufacturing residues. Regulatory agencies expect robust particle characterization using microscopy, spectroscopy, and particle counters, along with root cause investigations and corrective actions.

Regulatory and Quality Implications

Regulatory authorities increasingly emphasize container closure system suitability, E&L risk assessments, and stability studies that include packaging interactions. FDA, EMA, and ICH guidelines highlight the importance of packaging as part of the drug product control strategy.

Failure to address drug container interactions has resulted in warning letters, product recalls, and supply disruptions, reinforcing the need for proactive packaging science.

Packaging as a Lifecycle CQA

To ensure product integrity, packaging should be treated as a Critical Quality Attribute from early development to commercialization. A lifecycle approach includes:

• Material selection and supplier qualification
• Risk based E&L studies
• Compatibility and stability testing
• Inspection and monitoring programs
• Continuous improvement and change management

Integrating packaging into Quality by Design (QbD) frameworks enables early identification of risks and robust control strategies.

Conclusion

Packaging is no longer a passive container; it is a critical component of the drug product system. Treating packaging as a CQA across the product lifecycle is essential to ensuring product quality, regulatory compliance, and patient safety.

As pharmaceutical products become more complex particularly biologics and combination products the science of packaging must evolve from a supportive function to a strategic pillar of pharmaceutical development.